Keystone Financial Group Arrowhead Pharmaceuticals, Inc. Transaction History

Keystone Financial Group

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$26.2 - $36.08 $39,300 - $54,120	-1,500 Reduced 15.79%	8,000 $214,000
Q4 2022 Feb 07, 2023	BUY	$28.0 - $40.56 $49,000 - $70,980	1,750 Added 22.58%	9,500 $385,000
Q3 2022 Nov 10, 2022	BUY	$29.63 - $48.31 $7,407 - $12,077	250 Added 3.33%	7,750 $256,000
Q2 2022 Aug 05, 2022	BUY	$27.79 - $50.61 $41,685 - $75,915	1,500 Added 25.0%	7,500 $264,000
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $128,436 - $186,912	2,200 Added 57.89%	6,000 $375,000
Q4 2019 Feb 06, 2020	BUY	$28.14 - $73.01 $106,932 - $277,438	3,800 New	3,800 $241,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Keystone Financial Group, based on Form 13F filings with the SEC.

Stay updated on Keystone Financial Group with notifications on news.